Cargando…

Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study

BACKGROUND: Treatment interruption has been found to increase the risk of opportunistic infections and death among HIV-positive adults, posing a challenge to fully realizing antiretroviral therapy (ART). However, it has been observed that short-term interruption (<16 weeks) was not associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jing, Jin, Yan, Jiao, Kedi, Wang, Yao, Gao, Lijie, Li, Xinrui, Ma, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203161/
https://www.ncbi.nlm.nih.gov/pubmed/37228714
http://dx.doi.org/10.3389/fpubh.2023.1137132
_version_ 1785045569645838336
author Ma, Jing
Jin, Yan
Jiao, Kedi
Wang, Yao
Gao, Lijie
Li, Xinrui
Ma, Wei
author_facet Ma, Jing
Jin, Yan
Jiao, Kedi
Wang, Yao
Gao, Lijie
Li, Xinrui
Ma, Wei
author_sort Ma, Jing
collection PubMed
description BACKGROUND: Treatment interruption has been found to increase the risk of opportunistic infections and death among HIV-positive adults, posing a challenge to fully realizing antiretroviral therapy (ART). However, it has been observed that short-term interruption (<16 weeks) was not associated with significant increases in adverse clinical events. There remains a dearth of evidence concerning the interruption and resumption of ART after short-term discontinuation in China. METHODS: HIV-positive adults who initiated ART in Jinan between 2004 and 2020 were included in this study. We defined ART interruption as more than 30 consecutive days off ART and used Cox regression to identify predictors of interruption. ART resumption was defined as a return to ART care within 16 weeks following discontinuation, and logistic regression was used to identify barriers. RESULTS: A total of 2,506 participants were eligible. Most of them were male [2,382 (95%)] and homosexual [2,109 (84%)], with a median age of 31 (IQR: 26–40) years old. Of all participants, 312 (12.5%) experienced a treatment interruption, and the incidence rate of interruption was 3.2 (95% CI: 2.8–3.6) per 100 person-years. A higher risk of discontinuation was observed among unemployed individuals [adjusted hazard ratio (aHR): 1.45, 95% CI: 1.14–1.85], with a lower education level (aHR: 1.39, 95% CI: 1.06–1.82), those with delayed ART initiation (aHR: 1.43, 95% CI: 1.10–1.85), receiving Alafenamide Fumarate Tablets at ART initiation (aHR: 5.19, 95% CI: 3.29–8.21). About half of the interrupters resumed ART within 16 weeks, and participants who delayed ART initiation, missed the last CD4 test before the interruption and received the “LPV/r+NRTIs” regimen before the interruption were more likely to discontinue treatment for the long term. CONCLUSION: Antiretroviral treatment interruption remains relatively prevalent among HIV-positive adults in Jinan, China, and assessing socioeconomic status at treatment initiation will help address this issue. While almost half of the interrupters returned to care within 16 weeks, further focused measures are necessary to reduce long-term interruptions and maximize the resumption of care as soon as possible to avoid adverse clinical events.
format Online
Article
Text
id pubmed-10203161
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102031612023-05-24 Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study Ma, Jing Jin, Yan Jiao, Kedi Wang, Yao Gao, Lijie Li, Xinrui Ma, Wei Front Public Health Public Health BACKGROUND: Treatment interruption has been found to increase the risk of opportunistic infections and death among HIV-positive adults, posing a challenge to fully realizing antiretroviral therapy (ART). However, it has been observed that short-term interruption (<16 weeks) was not associated with significant increases in adverse clinical events. There remains a dearth of evidence concerning the interruption and resumption of ART after short-term discontinuation in China. METHODS: HIV-positive adults who initiated ART in Jinan between 2004 and 2020 were included in this study. We defined ART interruption as more than 30 consecutive days off ART and used Cox regression to identify predictors of interruption. ART resumption was defined as a return to ART care within 16 weeks following discontinuation, and logistic regression was used to identify barriers. RESULTS: A total of 2,506 participants were eligible. Most of them were male [2,382 (95%)] and homosexual [2,109 (84%)], with a median age of 31 (IQR: 26–40) years old. Of all participants, 312 (12.5%) experienced a treatment interruption, and the incidence rate of interruption was 3.2 (95% CI: 2.8–3.6) per 100 person-years. A higher risk of discontinuation was observed among unemployed individuals [adjusted hazard ratio (aHR): 1.45, 95% CI: 1.14–1.85], with a lower education level (aHR: 1.39, 95% CI: 1.06–1.82), those with delayed ART initiation (aHR: 1.43, 95% CI: 1.10–1.85), receiving Alafenamide Fumarate Tablets at ART initiation (aHR: 5.19, 95% CI: 3.29–8.21). About half of the interrupters resumed ART within 16 weeks, and participants who delayed ART initiation, missed the last CD4 test before the interruption and received the “LPV/r+NRTIs” regimen before the interruption were more likely to discontinue treatment for the long term. CONCLUSION: Antiretroviral treatment interruption remains relatively prevalent among HIV-positive adults in Jinan, China, and assessing socioeconomic status at treatment initiation will help address this issue. While almost half of the interrupters returned to care within 16 weeks, further focused measures are necessary to reduce long-term interruptions and maximize the resumption of care as soon as possible to avoid adverse clinical events. Frontiers Media S.A. 2023-05-09 /pmc/articles/PMC10203161/ /pubmed/37228714 http://dx.doi.org/10.3389/fpubh.2023.1137132 Text en Copyright © 2023 Ma, Jin, Jiao, Wang, Gao, Li and Ma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Ma, Jing
Jin, Yan
Jiao, Kedi
Wang, Yao
Gao, Lijie
Li, Xinrui
Ma, Wei
Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study
title Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study
title_full Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study
title_fullStr Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study
title_full_unstemmed Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study
title_short Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study
title_sort antiretroviral treatment interruption and resumption within 16 weeks among hiv-positive adults in jinan, china: a retrospective cohort study
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203161/
https://www.ncbi.nlm.nih.gov/pubmed/37228714
http://dx.doi.org/10.3389/fpubh.2023.1137132
work_keys_str_mv AT majing antiretroviraltreatmentinterruptionandresumptionwithin16weeksamonghivpositiveadultsinjinanchinaaretrospectivecohortstudy
AT jinyan antiretroviraltreatmentinterruptionandresumptionwithin16weeksamonghivpositiveadultsinjinanchinaaretrospectivecohortstudy
AT jiaokedi antiretroviraltreatmentinterruptionandresumptionwithin16weeksamonghivpositiveadultsinjinanchinaaretrospectivecohortstudy
AT wangyao antiretroviraltreatmentinterruptionandresumptionwithin16weeksamonghivpositiveadultsinjinanchinaaretrospectivecohortstudy
AT gaolijie antiretroviraltreatmentinterruptionandresumptionwithin16weeksamonghivpositiveadultsinjinanchinaaretrospectivecohortstudy
AT lixinrui antiretroviraltreatmentinterruptionandresumptionwithin16weeksamonghivpositiveadultsinjinanchinaaretrospectivecohortstudy
AT mawei antiretroviraltreatmentinterruptionandresumptionwithin16weeksamonghivpositiveadultsinjinanchinaaretrospectivecohortstudy